Anthropic plans to develop its own drugs, announces Claude Science

Anthropic announced at “The Briefing: AI for Science” that it is launching Claude Science, an AI workbench for scientists, and that it will develop drugs of its own, focusing on treatments for "neglected" diseases, though the company provided very few specifics about targets, trials, or partnerships.

What did Anthropic announce at the event?

Claude Science is an "AI workbench for scientists" that Anthropic presented as a single environment to pull fragmented tools and datasets together and to generate figures and visuals. Head of life sciences Eric Kauderer-Abrams said the company will focus on discovering treatments for "neglected" diseases, but Kauderer-Abrams did not say what Anthropic would do if it finds promising drug candidates. Anthropic has been hiring in life sciences, building wet labs, and as of writing had "several live applications hiring for life sciences roles."

How realistic is Anthropic actually developing drugs?

AI already plays roles across discovery, but turning AI outputs into approved medicines remains distant: experts say AI is used at "every single stage of drug discovery," but experiments and clinical testing remain necessary. Namshik Han noted that AI is applied from finding and improving compounds to supporting research and clinical trials; Frank von Delft warned AI models "haven't yet come close to making experiments unnecessary." No AI-designed drug has yet made it through clinical trials and FDA approval to reach market, and experts expect the process to take at least "the better part of a decade" for any meaningful clinical payoff.

The reporting stressed two bottlenecks. First, public, high-quality experimental data about how chemicals behave in the body remains limited, which can slow development. Second, real-world testing for efficacy, toxicity, formulation, and delivery requires skilled workers, capital, and time. Even when AI suggests molecules or targets, those candidates must still be validated in labs, animals, and human trials, stages where many promising leads fail.

What would Anthropic actually do differently or compete on?

Anthropic occupies an unusual position: it sells AI tools to biotech and pharma while announcing intentions to act as a drug developer itself. That places it alongside AI-first drug companies and pharma efforts, joining companies such as Insilico and Isomorphic Labs as well as Big Pharma groups already building AI tools. The company has framed Claude Science as a way to "dramatically accelerate the pace of scientific discovery and the development of healthcare interventions," and its frontier models could be used to search across chemical and biological possibilities, suggest molecules, identify new disease targets, or find new uses for existing drugs. The company, however, has not explained whether it would partner for lab work, animal testing, clinical trials, or manufacturing.

Why it matters

Anthropic moving from toolmaker toward developer tightens the overlap between AI platform vendors and end-stage drug developers. That raises conflicts of interest for customers who may also be competitors, and it concentrates more discovery capacity inside a handful of frontier-AI firms. It also underlines a broader industry reality: many major drug companies already use AI for discovery and research, but converting AI ideas into approved medicines still requires conventional experimental pipelines and lengthy trials.

What to watch

Watch Anthropic's hiring and lab footprint, specifically whether its "several live applications hiring for life sciences roles" turn into staffed research teams and functioning wet labs. Also watch for any announcement of first disease targets, disclosure of partnerships for animal or clinical testing, or movement of an AI-suggested candidate into formal preclinical or clinical trials, milestones the company has not yet described.

Date and context note: the announcement came at "The Briefing: AI for Science" and was reported on July 3, 2026. Experts quoted in the announcement stressed both AI's broad role in discovery and the remaining experimental and regulatory barriers to getting AI-designed drugs to patients.